Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, today announced the closing of a $30 million financing. New investor OrbiMed joined existing investor Fidelity Biosciences in the round.
"Gene therapy has the potential to radically change the treatment paradigm for numerous rare diseases," said Rishi Gupta, private equity partner at OrbiMed. "Dimension's access to best-in-class AAV vector technology puts it at the forefront of developing in vivo gene therapy treatments, one of the most promising approaches in the field. We look forward to working with the Dimension team to realize the potential of gene therapy in areas of high unmet medical need."
"We are very pleased to welcome OrbiMed to our syndicate," said Ben Auspitz, chairman of Dimension Therapeutics and a partner at Fidelity Biosciences. "OrbiMed has helped build many start-ups with break-through science into commercially successful healthcare companies. Rishi and the OrbiMed team will be valuable partners and strategic advisors as we continue to advance our novel gene therapy programs for patients with rare diseases."